Keywords
Penicillin
Pruritus
Anxiety
Allergy
Antibiotics
How to Cite
Abstract
OBJECTIVE: To evaluate the single-blind, placebo-controlled penicillin challenge in HIV/AIDS patients without prior skin testing.
METHODS: A prospective study was conducted in patients attending the Outpatient Center for the Prevention and Care of AIDS and Sexually Transmitted Infections in Puebla, Mexico. Statistical analysis included percentages, frequencies, means, standard deviations, and medians; c2 (Fisher's exact test), one-way Kruskal-Wallis test, Cramer's V test; and binomial distribution. The Statistical Package for the Social Sciences 26 (SPSS) was used for data analysis.
RESULTS: A total of 104 patients aged 18 years or older (mean age 34.6 ± 10.5 years) were registered: women (n = 3; 2.9%), men (n = 101; 97.1%). Regarding the study variables, the following results were found: 7 (6.7%) positive penicillin challenges, 2 (1.9%) positive placebo challenges, and 95 (91.3%) no reaction; effect size V = 0.038, p = 0.701 (placebo-penicillin), V = 1, p = 0.000 (no reaction-penicillin reaction), with a binomial distribution and B(7; 0.1533). Regarding comorbidities, a difference was observed between the groups (p<0.05) in symptoms during the challenge: pruritus in the penicillin reaction group (p = 0.03) and anxiety in the placebo group (p = 0.005).
CONCLUSIONS: In HIV/AIDS patients categorized as low risk, the single-blind, placebo-controlled penicillin challenge allowed for the elimination of potential allergy, because the benefit of the antibiotic is crucial for a successful disease outcome.
KEYWORDS: HIV-AIDS; Penicillin; Pruritus, Anxiety; Allergy; Antibiotics.
References
1. Phillips E, Mallal S. Drug hypersensitivity in HIV. Curr Opin Allergy Clin Immunol. 2007; 7 (4): 324-30. doi: 10.1097/ACI.0b013e32825ea68a.
2. Peter J, Choshi P, Lehloenya RJ. Drug hypersensitivity in HIV infection. Curr Opin Allergy Clin Immunol. 2019; 19 (4): 272-282. doi: 10.1097/ACI.0000000000000545.
3. Trubiano JA, Vogrin S, Chua KYL, Bourke J, et al. Development and Validation of a Penicillin Allergy Clinical Decision Rule. JAMA Intern Med. 2020; 180 (5): 745-752. doi: 10.1001/jamainternmed.2020.0403.
4. Jeimy S, Wong T, Ben-Shoshan M, Copaescu AM, et al. Drug allergy. Allergy Asthma Clin Immunol. 2025; 20 (Suppl 3): 78. doi: 10.1186/s13223-024-00936-1. PMID: 39844329; PMCID: PMC11755868.
5. Lillis RA, Barbee LA, McNeil CJ, Newman L, et al. Randomized Multicenter Trial for the Validation of an Easy-to-Administer Algorithm to Define Penicillin Allergy Status in Sexually Transmitted Infection Clinic Outpatients. Clin Infect Dis. 2024; 78 (5): 1131-1139. doi: 10.1093/cid/ciae064.
6. DesBiens M, Scalia P, Ravikumar S, Glick A, Newton H, et al. A Closer Look at Penicillin Allergy History: Systematic Review and Meta-Analysis of Tolerance to Drug Challenge. Am J Med. 2020; 133 (4): 452-462.e4. doi: 10.1016/j.amjmed.2019.09.017.
7. Iammatteo M, Lezmi G, Confino-Cohen R, Tucker M, et al. Direct Challenges for the Evaluation of Beta-Lactam Allergy: Evidence and Conditions for Not Performing Skin Testing. J Allergy Clin Immunol Pract. 2021; 9 (8): 2947-2956. doi: 10.1016/j.jaip.2021.04.073.
8. Ramsey A, Rozario C, Stern J. Direct challenges are the gold standard for most antibiotic allergy evaluations. Ann Allergy Asthma Immunol. 2023; 131 (4): 427-433. doi: 10.1016/j.anai.2023.03.033.
9. Castells M, Khan DA, Phillips EJ. Penicillin Allergy. N Engl J Med. 2019; 381 (24): 2338-2351. doi: 10.1056/NEJMra1807761.
10. Banks TA, Tucker M, Macy E. Evaluating Penicillin Allergies Without Skin Testing. Curr Allergy Asthma Rep. 2019; 19 (5): 27. doi: 10.1007/s11882-019-0854-6.
11. Li J, Shahabi-Sirjani A, Figtree M, Hoyle P, Fernando SL. Safety of direct drug provocation testing in adults with penicillin allergy and association with health and economic benefits. Ann Allergy Asthma Immunol. 2019; 123 (5): 468-475. doi: 10.1016/j.anai.2019.08.005.
12. Brillant-Marquis F, Proulx É, Ratnarajah K, Lavoie A, et al. Safety of Direct Drug Provocation for the Evaluation of Penicillin Allergy in Low-Risk Adults. J Allergy Clin Immunol Pract. 2024; 12 (2): 451-457.e2. doi: 10.1016/j.jaip.2023.10.035.
13. Khan DA, Banerji A, Blumenthal KG, Phillips EJ, et al. Drug allergy: A 2022 practice parameter update. J Allergy Clin Immunol. 2022; 150 (6): 1333-1393. doi: 10.1016/j.jaci.2022.08.028.
14. Iammatteo M, Ferastraoaru D, Koransky R, Alvarez-Arango S, et al. Identifying Allergic Drug Reactions Through Placebo-Controlled Graded Challenges. J Allergy Clin Immunol Pract. 2017; 5 (3): 711-717.e2. doi: 10.1016/j.jaip.2016.09.041.
15. Samarakoon U, Accarino J, Wurcel AG, Jaggers J, Judd A, Blumenthal KG. Penicillin allergy delabeling: Opportunities for implementation and dissemination. Ann Allergy Asthma Immunol. 2023; 130 (5): 554-564. doi: 10.1016/j.anai.2022.12.023.
16. Mill C, Primeau MN, Medoff E, Lejtenyi C, et al. Assessing the Diagnostic Properties of a Graded Oral Provocation Challenge for the Diagnosis of Immediate and Nonimmediate Reactions to Amoxicillin in Children. JAMA Pediatr. 2016; 170 (6): e160033. doi: 10.1001/jamapediatrics.2016.0033.
17. Copaescu AM, Li L, Blumenthal KG, Trubiano JA. How to Define and Manage Low-Risk Drug Allergy Labels. J Allergy Clin Immunol Pract. 2024; 12 (5): 1095-1106. doi: 10.1016/j.jaip.2024.03.021.
18. World Medical Association. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Participants. JAMA. 2025; 333 (1): 71-74. doi: 10.1001/jama.2024.21972.
19. CDC. 1992 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1993; 41 (RR–17):961-2.
20. Copaescu AM, Vogrin S, James F, Chua KYL, et al. Efficacy of a Clinical Decision Rule to Enable Direct Oral Challenge in Patients With Low-Risk Penicillin Allergy: The PALACE Randomized Clinical Trial. JAMA Intern Med. 2023; 183 (9): 944-952. doi: 10.1001/jamainternmed.2023.2986.
21. Blumenthal KG, Smith LR, Mann JTS, et al. Reaction Risk to Direct Penicillin Challenges: A Systematic Review and Meta-Analysis. JAMA Intern Med. 2024; 184 (11): 1374-1383. doi:10.1001/jamainternmed.2024.4606
22. Koo G, Stollings JL, Lindsell C, Dear ML, et al. Low-risk penicillin allergy delabeling through a direct oral challenge in immunocompromised and/or multiple drug allergy labeled patients in a critical care setting. J Allergy Clin Immunol Pract. 2022; 10 (6): 1660-1663.e2. doi: 10.1016/j.jaip.2022.01.041.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright (c) 2026 Revista Alergia México